Bullish indicating open at $55-$60, IPO prices at $37
BOSTON—Ronald Silver, the Principal Accounting Officer at Ironwood Pharmaceuticals Inc (NASDAQ:IRWD), recently sold 12,048 shares of the company’s Class A common stock. The transaction comes as the stock has experienced significant pressure, down over 87% in the past year according to InvestingPro data. The shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. This transaction, which took place on February 10, 2025, resulted in a total sale value of $21,204, with a weighted average price of $1.76 per share. The shares were sold in multiple transactions at prices ranging from $1.60 to $1.84. Following the sale, Silver holds 279,655 shares in the company. While current trading suggests the stock is undervalued, InvestingPro analysis reveals 10+ additional investment insights and a comprehensive research report available for subscribers.
In other recent news, Ironwood Pharmaceuticals has been making significant strategic changes. The firm recently announced a workforce reduction of about 50% as it shifts its focus to the development of apraglutide, a treatment for short bowel syndrome. The restructuring, which is expected to streamline operations and reduce costs, was followed by disappointing full-year revenue guidance that fell short of consensus expectations. The firm anticipates incurring restructuring charges of about $20 to $25 million, but expects to realize annual operating expense savings of approximately $55 to $60 million.
Ironwood Pharmaceuticals was also recently excluded from the S&P SmallCap 600 index due to its current market capitalization no longer aligning with the small-cap market space. JMP Securities has adjusted its financial outlook on Ironwood, setting a new price target of $14, down from the previous target of $23, while maintaining a Market Perform rating. The firm highlights the potential of apraglutide as a key asset for future value despite ongoing difficulties with LINZESS, Ironwood’s flagship product.
These recent developments reflect Ironwood’s strategic decisions as it navigates the competitive pharmaceutical landscape. The company’s focus is now firmly on advancing apraglutide and ensuring long-term growth, despite immediate market reactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.